Enter your keywords
Overview Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing. Insulin aspart Sanofi (Trurapi®▼) is the first biosimilar of insulin aspart (NovoRapid®). It is licensed for the treatment of diabetes […]
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs. Download the full review below to read more.
This report looks at prescribing trends in primary care for Drugs affecting bone metabolism at CCG and STP level with selected substances analysed at presentation level and also explores associations between prescribing and hospital admissions relating to hip fractures. If you have any queries about the content of the report please contact us at firstname.lastname@example.org […]
Overview New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs. Ultra-rapid acting insulin lispro (Lyumjev®▼, Lilly) is a new formulation of insulin lispro with added treprostinil and citrate to produce a more […]
This report looks at prescribing trends in primary care for Drugs used in Diabetes at CCG and STP level with particular focus on insulins, anti-diabetic drugs and diagnostic & monitoring devices. Prescribing data is weighted with QoF registers, and also uses HES data to measure prescribing to outcomes. If you have any queries about the […]
The sodium-glucose co-transporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin and ertugliflozin are licensed for the improvement of glycaemic control in adults with type 2 diabetes, a population at increased risk of cardiovascular events. Recent clinical trials and cohort studies have assessed whether the SGLT2 inhibitors reduce this risk. Download the full review below to read […]
The glucagon-like peptide 1 receptor agonists (GLP1RAs) dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide are licensed for the improvement of glycaemic control in adults with type 2 diabetes, a population which is also at increased risk of cardiovascular events. Good quality evidence assessed the effect of these drugs on cardiovascular outcomes. Download the full review below […]
This publication highlights the variation in flash glucose monitoring prescribing, specifically Freestyle Libre, in people with Type 1 diabetes mellitus (T1DM). Prescribing is considered both in terms of the percentage of unique people prescribed this type of monitoring system and also the prescribing volume in 19/20 relative to the NHS England (NHSE) National funding arrangements. […]
Semaglutide (Rybelsus®▼) is the first oral GLP1 receptor agonist (GLP1RA), for the treatment of adults with type 2 diabetes mellitus. Download the full review below to read more.
Comparison tables are produced for prescribers and medicines management teams. They are designed to assist in prescribing and decision-making within a specific therapeutic area. Several glucagon-like peptide receptor 1 agonists are marketed, with differences in licensing, formulation, and administration. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these […]